New York A 10967: Enhances transparency in the prescription drug supply chain

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
A10967 Summary:

BILL NOA10967 

&nbsp

SAME ASSAME AS S09985

&nbsp

SPONSORBlumencranz

&nbsp

COSPNSR

&nbsp

MLTSPNSR

&nbsp

Amd §280-a, add §278-b, Pub Health L; amd §6810, Ed L

&nbsp

Enacts the "foreign drug transparency act" to provide information on the origin, manufacture and distribution of prescription drugs; requires a pharmacy benefit manager to maintain, and make available to pharmacies, health plans, and patients upon request, supply chain information for prescription drugs covered under its network.

Go to top A10967 Actions:

BILL NOA10967 

&nbsp

04/14/2026referred to health

Go to topA10967 Committee&nbspVotes:

Go to topA10967 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topA10967 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 10967

 IN ASSEMBLY

 April 14, 2026
 ___________

 Introduced by M. of A. BLUMENCRANZ -- read once and referred to the
 Committee on Health

 AN ACT to amend the public health law and the education law, in relation
 to enhancing transparency in the prescription drug supply chain,
 including disclosure of country of origin and manufacturer information

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. This act shall be entitled the "foreign drug transparency
 2 act".
 3 § 2. Legislative intent. The legislature hereby finds and declares
 4 that:
 5 1. The United States prescription drug supply chain is increasingly
 6 globalized, with a significant portion of finished drug products and
 7 active pharmaceutical ingredients (APIs) manufactured outside of the
 8 United States.
 9 2. Patients, pharmacists, and health care providers often lack access
 10 to clear and accessible information regarding the origin and manufactur-
 11 ing of prescription drugs.
 12 3. Transparency regarding the origin, manufacture, and distribution of
 13 prescription drugs is essential to ensuring patient confidence, informed
 14 decision-making, and supply chain accountability.
 15 4. The legislature recognizes and supports ongoing bipartisan federal
 16 efforts, including the CLEAR LABELS Act, to require disclosure of drug
 17 manufacturing and supply chain information.
 18 5. It is the intent of this act to complement federal law by ensuring
 19 that such information is readily accessible to consumers at the point of
 20 dispensing within New York State.
 21 § 3. Subdivision 1 of section 280-a of the public health law is
 22 amended by adding three new paragraphs (j), (k), and (l) to read as
 23 follows:
 24 (j) "Active pharmaceutical ingredient" or "API" means any substance or
 25 component intended to furnish pharmacological activity in the diagnosis,
 26 cure, mitigation, treatment, or prevention of disease.

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD15453-01-6

 A. 10967 2

 1 (k) "Original manufacturer" means the entity that performs the final
 2 substantial manufacturing step prior to the introduction of an API or
 3 finished drug product into interstate commerce.
 4 (l) "Supply chain information" means:
 5 (i) The country of origin of the finished drug product;
 6 (ii) The country or countries of origin of any active pharmaceutical
 7 ingredients;
 8 (iii) The name and place of business of the original manufacturer of
 9 the API;
 10 (iv) The name and place of business of the manufacturer of the
 11 finished drug product; and
 12 (v) The name and place of business of any packer or distributor, if
 13 applicable.
 14 § 4. Section 6810 of the education law is amended by adding a new
 15 subdivision 1-b to read as follows:
 16 1-b.(a) In addition to the labeling requirements pursuant to subdivi-
 17 sion one of this section, a pharmacy shall ensure that, at the time a
 18 prescription drug is dispensed to a patient, supply chain information,
 19 as defined in paragraph (l) of subdivision one of section two hundred
 20 eighty-a of the public health law, is made readily accessible to the
 21 patient.
 22 (b) Such information shall be provided through one or more of the
 23 following methods:
 24 (i) A clearly visible notation on the prescription label or accompany-
 25 ing documentation indicating th